Pyrosequencing of IDH1 and IDH2 Mutations in Brain Tumors and Non-neoplastic Conditions
Authors:
- 1 December 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Diagnostic Molecular Pathology
- Vol. 21 (4) , 214-220
Abstract
The molecular profiling of brain tumors, including testing for MGMT promoter methylation and chromosome 1p/19q deletion, can provide both diagnostic and prognostic information that may guide treatment. Isocitrate dehydrogenase (IDH) mutation testing is a recent addition to this armamentarium of molecular pathology tools that similarly provides both diagnostic (eg, glioma vs. gliosis) and prognostic information. Herein, we describe a pyrosequencing-based approach to IDH1 and IDH2 mutation testing and its application to 139 neoplastic and non-neoplastic central nervous system specimens. Several technical issues encountered in the development of the assay, particularly with regard to the optimization of the sequencing reaction, are described. Mutations in IDH1 codon 132 or IDH2 codon 172 were identified in 31.2% of all screened cases and 46.2% of screened World Health Organization grade I to IV gliomas (n=93), with mutations arising exclusively in grade II to IV oligodendroglial, astrocytic, or mixed oligoastrocytic neoplasms. Examination of the relationship between the mutation status and other pertinent variables demonstrated a significant male predominance among IDH1-mutated gliomas, most notably in grade III to IV astrocytic neoplasms. A significant association between IDH1/IDH2 mutation and 1p/19q deletion was also seen (Kendall τ coefficient=0.26, P=0.018), although several cases with 1p/19q deletion were IDH1/IDH2 wild type.Keywords
This publication has 12 references indexed in Scilit:
- Update on molecular findings, management and outcome in low-grade gliomasNature Reviews Neurology, 2010
- A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical SamplesThe Journal of Molecular Diagnostics, 2010
- Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomasJournal of Neuro-Oncology, 2010
- Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosisActa Neuropathologica, 2010
- Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain TumorsBrain Pathology, 2009
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in GliomasJournal of Clinical Oncology, 2009
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomasActa Neuropathologica, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Analysis of the IDH1 codon 132 mutation in brain tumorsActa Neuropathologica, 2008
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008